Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Inclusion Criteria: * Male or female, between 18 and 65 years of age (inclusive) at the time of Screening. * Documented diagnosis of ADPKD by imaging or genetic analysis previously treated with tolvaptan for that indication. * Screening eGFR ≥ 20 mL/min/1.73 m\^2. * Body mass index (BMI) between 18 and 35 kg/m\^2 (inclusive) at the time of Screening. * Documented history of: * Based on upper limit of normal (ULN): At least 2 elevated alanine aminotransferase (ALT) levels; 1 ALT level \>2 x ULN and 1 ALT level \>3 x ULN while the participant was receiving tolvaptan, or within 4 weeks after tolvaptan discontinuation, with no other explanation for the ALT elevations. The 2 elevated ALT measurements could be recorded during the same instance of liver injury or during distinct instances; OR * Based on the participant's stable baseline as determined by the Investigator: At least 2 elevated ALT levels; 1 ALT level \>2 x the participant's stable baseline level and 1 ALT level \>3 x the participant's stable baseline level while the participant was receiving tolvaptan, or within 4 weeks after tolvaptan discontinuation, with no other explanation for the ALT elevations; provided that at least one ALT elevation was \>2 x ULN. The 2 elevated ALT measurements could be recorded during the same instance of liver injury or during distinct instances; OR * A pattern of ALT elevations deemed by the Investigator to be consistent with tolvaptan liver injury with no other explanation for the…